Date: Wed. 06/23/21 Time: 10:00 AM PT – 2:30 PM PT
Timeline of Event (PT) Content Duration
10:00 AM – 10:05 AM Host Introduces Event & Moderator 5 min
10:05 AM – 10:10 AM Moderator Introduces Webinar 1 Panel 5 min
10:10 AM – 10:45 AM Panel Discussion 35 min
10:45 AM – 10:55 AM Audience Q&A 10 min
10:55 AM – 11:00 AM Host Closing Remarks & Thank Sponsors 5 min
11:55 AM – 11:30 AM Web 1 Breakout Session 30 min
11:30 AM – 11:35 AM Host Introduces Webinar 2 & Moderator 5 min
11:35 AM – 11:40 AM Moderator Introduces Webinar 2 Panel 5 min
11:40 AM – 12:15 PM Panel Discussion 35 min
12:15 PM – 12:25 PM Audience Q&A 10 min
12:25 PM – 12:30 PM Host Closing Remarks & Thank Sponsors 5 min
12:30 PM – 1:00 PM Web 2 Breakout Session 30 min
1:00 PM – 1:05 PM Host Introduces Webinar 3 & Moderator 5 min
1:05 PM – 1:10 PM Moderator Introduces Webinar 3 Panel 5 min
1:10 PM – 1:45 PM Panel Discussion 35 min
1:45 PM – 1:55 PM Audience Q&A 10 min
1:55 PM – 2:00 PM Host Closing Remarks & Thank Sponsors 5 min
2:00 PM – 2:30 PM Web 3 Breakout Session 30 min
• Psychedelics Today
• CFN Media Group
• Global Go
• Zuber Lawler
Host, Paul Rosen, Executive Chairman, Global Go
Paul Rosen is a noted career entrepreneur, management consultant and public speaker.
Paul was a co-founder of PharmaCan Capital Corp. doing business as The Cronos Group (NASDAQ: CRON; TSX: CRON) and served as its first President and CEO. Paul has held board positions with a number of publicly traded cannabis companies, and serves as the Executive Chairman of Global Go, a leading advisory focused on the global regulated cannabis and psychedelic industries. Paul currently serves as interim CEO of 1933 Industries, a Las Vegas based vertically integrated cannabis operator. Paul is also a Director at Delic Holdings Inc. (DELC:CNSX), a leader in the nascent and growing space of psychedelic wellness.
WEB 1: “CLEARING THE HAZE- WHAT’S LEGAL TODAY”
Over the past two years, North America has seen a number of jurisdictions take real steps towards decriminalizing and legalizing psychedelic substances, most notably psilocybin. From successful voter initiatives in Denver, CO, Washington, DC, and Santa Cruz, CA to successful statewide measures in Oregon, psychedelics are on its way towards legalization. In 2019 the FDA has approved treatment for ketamine-based nasal spray Spravato and granted “breakthrough therapy designation” to two psilocybin formulas for depression treatment. This panel will focus on clarifying the legal landscape so that both public and private companies can understand the market opportunities associated with government-approved psychedelics.
Moderator, Dr. Jayashree Mitra, Partner, Zuber Lawler
Dr. Jayashree Mitra focuses on patent litigation, IPR and PGR proceedings, and trade secret matters. Dr. Mitra has litigated drug patents for one of the biggest pharmaceutical companies in the world. She has experience successfully litigating a diverse range of products in the pharmaceutical and cannabis industries, and is increasingly focused on the future landscape of litigation in the psychedelics space. She also has extensive experience advising clients in relation to psychedelics and cannabis related technology, including as to developing their intellectual property portfolios, and navigating the complex regulatory pathways before the FDA. She works in federal courts and before the International Trade Commission. She earned a Ph.D. in Pharmacology from Yale University and her J.D. from Northwestern University School of Law, where she was a member of the Law Review.
Panelist, Timothy Ko, CEO, Entheon Biomedical
Timothy has a background of leading private ventures in the Investor Relations, Retail and Technology sectors. With a professional emphasis on disruptive technologies that challenge the status quo, Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of current mental health and addiction treatment options, and through his exposure to psychedelics, which he credits with saving his life.
Panelist, Tim Moore, CEO, HAVN Life
Tim Moore is the former CEO of Green Growth Brands, leading the company from its IPO through to January 2019, reaching a nearly billion dollar market cap. Prior to that, Mr. Moore had a successful career in packaged goods where he spent 18 years at Clorox, with the last eight serving as president. Before that, he spent seven years at Brita as managing director of the North America foodservice and retail businesses.
Mr. Moore joined HAVN Life in 2020 and is now leveraging his past leadership experience in the cannabis industry to create an effective path to success for HAVN Life, whose mission is to use evidence-informed research to unlock human performance and help to define and standardize the future of modern medicine.
Panelist, Hadas Alterman, Founding Partner, Plant Medicine Law Group LLP
Hadas is an Israeli-American attorney, born in Jerusalem and raised in the San Francisco Bay Area. She has a J.D. from Berkeley Law and a B.A. in Community Studies/Agriculture & Social Justice from the University of California at Santa Cruz. Hadas advises companies on matters of regulatory compliance, policy advocacy, risk management, strategic planning, revenue models, corporate governance, and dispute resolution. Prior to founding PMLG, she worked with a leading cannabis law firm in San Francisco. Hadas has led clients through successful cannabis license applications in California, Maryland, Ohio, and Pennsylvania; served as counsel to equity applicants in Oakland and San Francisco, and works with legacy growers in the Emerald Triangle. Hadas is a former restorative justice practitioner and community organizer dedicated to using the law to expand equitable access to plant medicine. Hadas was the Policy Director of NYMHA, an organization that she co-founded that successfully lobbied for the introduction of a New York bill to decriminalize psilocybin by statute, and is a Board Member of the Psychedelic Bar Association. She also serves on the Equity Subcommittee of the Oregon Psilocybin Advisory Board.
Panelist, David Wood, PhD, Chief Legal Officer & General Counsel, Psygen Industries Ltd.
David Wood is a lawyer and patent agent with a PhD in Structural Biochemistry from the University of Saskatchewan. He is an expert in intellectual property law and regulatory law (controlled substances, cannabis and drug product commercialization).
Broadening regulated access to psychedelics is my top professional priority and my top personal priority outside of my family. I am grateful and fortunate to be in a position to focus my career on advancing this priority. In my role as Chief Legal Officer and General Counsel to Psygen Industries Ltd., I am privileged to work as part of a team of effective and motivated professionals. Through Psygen’s contract manufacturing services and research, we are motivated to bring back LSD, advance understanding of the therapeutic possibilities presented by psychedelics and contribute to the global supply chain for these powerful compounds.
My understanding of intellectual property, controlled substance regulations and drug product commercialization dovetails with my understanding of organic chemistry and biochemistry to bring significant value in work with psychedelics. Twelve years of experience working at Canada’s largest national law firm, including four years of co-chairing a psychedelics and cannabis focus group, have provided me with the experience and perspective to provide high-impact and effective legal advice in this specialized and dynamic space.
WEB 2: KETAMINE CLINICS DO’S AND DON’TS
Ketamine, one of the world’s most commonly used drugs for more than 50 years, has recently evolved as what can only be described as a phenomenon in treating severe depression and other mental health disorders. A recent boom in the proliferation of ketamine infusion clinics opening up across North America has left many wondering what these means for behaviorial healthcare treatment and how to succeeed in this new industry. This panel will focus on the logistics of opening and operating a ketamine clinc given the complex interplay of federal, state, and local laws.
Moderator, Tegan Joan, Founder, Acid-Channel Inc.
Experienced Chief Executive Officer with a demonstrated history of working in different areas of development. Skilled in ESG and Corporate Social Responsibility, Sustainable Business, Management, Community Engagement, and Policy Analysis. Strong business development professional with a Master of Science (MSc) focused in Integrated Studies (Carbon Accounting, Corporate Social Responsibility and Climate Policy Design) from The University of British Columbia.
Panelist, Ali Mohammed, PhD, CEO, Lyte Medical
Our focus at Lyte Medical is taking the stress out of having to physically see a doctor. Our Telemedicine platform allows patients to speak to a doctor from the comfort of their own home. At Lyte Medical we aim to make our patients interaction with health care professionals as simple as possible. Our technology driven clinic focuses on patients needs and strives to enhance their overall medical experience.
At Lyte Clinics we strive to be the best Health Canada approved telemedicine clinic in Canada. Appointments are completely covered with your provincial health card, no doctor referral is needed and we are available in almost every Province. Our quick and easy system allows you to fill out your intake forms, see the doctor, and order from on of our 24 Licensed Producers of your choosing all from the comfort of your own home. Lyte has helped thousands of patients and our goal has always been to improve the lives of our patients with high- quality patient care, education and service that is readily accessible. Lyte is committed to continuously enrich people’s lives so they can live a happy and healthy life. [email protected]
Panelist, Matt Stang , CEO, Delic Corp.
Matt Stang was an Owner and Operator of High Times, the most recognized brand in Cannabis, for 17 years prior to its sale to a private equity fund, and during that time he helped legalize Cannabis in multiple states, launched the Cannabis Cup in America, and helped build the legal cannabis industry. For almost 20 years he has met and interacted with all corners within the cannabis community. As one of the most connected people in the Alternative Drug space, he helped found DELIC two years ago as one of the first psychedelic corporations. His expertise in business includes marketing, branding, business development and product viability.
Panelist, Ronan Levy, Co-Founder & Executive Chairman, Field Trip
Believing that you should never hesitate to trade your cow for a handful of magic beans, Ronan has built a career out of doing things that others say cannot be done. Ronan started his career as a securities lawyer at Blake, Cassels & Graydon LLP but left that after realizing he was much too creative for the profession of law. Since then, Ronan has helped launch business across a number of industries from gold, to cannabis, and, most recently, in psychedelics where he is a Co-founder and the Executive Chairman of Field Trip Health Ltd. (TSX: FTRP, OTCQX:FTRPF).
Panelist, Kazi Zayn Hassan, MD, Chief Medical Officer, Nue Life Health
Dr. Kazi (Zayn) Hassan specializes in Physical Medicine and Rehabilitation after training at Jackson Health Systems/University of Miami/Miami VA after graduating from Tufts University School of Medicine in Boston, MA. His current focus is in the field of integrative psychiatry, particularly in the field of psychedelic therapies.
His goal is to translate clinical research and apply an analytical framework to help providers drive better patient outcomes through technology and data science. He is a member of the American Society of Ketamine Physicians, Integrative Psychiatric Institute Fellowship Program, Psychedelic Assisted Therapy Program (IPI), and Ketamine Training Center. He strives to attain truly transformative and sustainable changes that promote overall brain health and mental wellness.
WEB 3: INTERESTED IN INVESTING IN PSYCHEDELICS?
Psychedelics are on the precipice of legalization and family offices and high-net worthy individual investors are eyeing early stage investments in this new market. In North America, dozens of companies have already gone public, with 25 companies listed on the Canadian Stock Exchange. On this panel we will be discussing identifying opportunities and avoiding pitfalls when investing in psychedelics.
Moderator, Anna Serin, Director of Listings Development, Canadian Securities Exchange
Ms. Serin has 20 years of experience in securities and corporate finance. She has an unwavering passion, perseverance and commitment to the capital markets and investment industry. She started her education in Business and Psychology, accomplished her brokerage and wealth management designations with honours and real estate licensing via Sauder School of Business.
Anna has worked with public companies providing all of their corporate and restructuring needs in the small cap space. She has aided companies with financings, financial reporting and maintenance, debt settlement and negotiations as well as all public disclosure and filings. She joined as Director of Listings Development with the Canadian Securities Exchange in 2016 and focuses on many areas of business and professional development initiatives within the community. Ms. Serin sits on the Corporate Finance committee with the BC Securities Commission as well as the Marketing and Communication Committee with AMEBC.
o [email protected]
Panelist, Greg Benson, CEO, Releave Therapeutics
Greg currently leads ReLeave Therapeutics as CEO, with responsibility for business growth and ongoing efforts with international expansion into emerging markets with respect to medical cannabis and psychedelics.
In his previous role with one of Canada’s first and largest medical cannabis clinic companies, Natural Health Services, he served as Senior Vice President working closely with the President. Benson’s leadership expanded beyond the typical boundaries of an executive where he has driven many strategic initiatives having a positive impact on multiple business areas.
Before joining Natural Health Services in 2016, Benson served as President/Founder of Health Matters International, where he grew revenues to $21 million globally over a 10-year period. He was responsible for building, growing and maintaining a successful International Health Care company with divisions in pharmaceuticals, OTC products, international medical surgeries, diabetes and cancer products. Greg developed an international pharmacy platform with partners in Italy, London UK, India, New Zealand, Australia, USA, South Africa and Canada where patients were offered a choice where to receive their prescription medication. Expanding into medical travel, Benson contracted with hospitals in Panama, Costa Rica, Los Cabo and Barbados where they offered medical surgeries and procedures in collaboration with the patient’s local physician.
Benson’s shared passion for healthcare and business started when he held various positions with tier 1 pharmaceutical companies such as Pfizer and AstraZeneca. Over his 8 years in the pharmaceutical industry, he learned many skills and became very knowledgeable in the global healthcare industry which led him to start his own International Healthcare Company.
Panelist, Harrison Keenan, Senior VP, CannAccord Genuity
Harrison Keenan has worked in the financial services industry since 1998. Providing timely investment advice, complementary financial planning and excellent customer service is his pledge to clients.
After entering the financial industry in 1998 as an analyst, he quickly moved to develop his own client base as an Investment Advisor.
He believes the client must always come first, and every client is unique. Harrison works hard to understand what each individual needs and to tailor solutions that meets their unique criteria.
An avid golfer, ultimate Frisbee player, competitive runner and cyclist, Harrison keeps physically busy every chance he can get. He is also a proud supporter of UTS, Care-Alive, St Michael’s Hospital, JDRF, UWGT, and “Movember”, among other causes.
Panelist, Josh Lawler, Partner, Zuber Lawler
Josh Lawler handles M&A, finance and corporate matters for private equity groups, and public and private companies, both domestically and internationally. He has also represented leading cannabis companies for over 14 years, and has more recently been at the cutting edge of legal work in the psychedelics space as well. Josh has extensive experience with complex deals relating to alternative medicines. He counsels cannabis and psychedelics companies on acquisitions and mergers, and post-acquisition and post-merger integration. His work with both leading cannabis, psychedelics, and leading blockchain companies positions him perhaps uniquely well to advise as to the intersection of plant, fungus, and blockchain technologies. Josh holds a B.S. from Duke University, and is a cum laude graduate of Northwestern University School of Law, and earned his B.S. and B.A. from Duke University.